Author

Peter Fletcher

Observed names: P Fletcher, P. Fletcher

Institutions: Cancer Research UK Clinical Trials Unit, University of Birmingham

Observed institutions: Bristol-Myers Squibb (United States), Cancer Research UK Clinical Trials Unit, University of Southampton, University College London, University of Birmingham

ORCID: 0000-0001-5905-831X

Observed ORCID: 0000-0001-5905-831X

OpenAlex ID: A5022636307

The National Lung Matrix Trial of personalized therapy in lung cancer

2020 · Gary Middleton, Peter Fletcher, et al. · Nature · 151

The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study

2021 · Vandana M. Sagar, Kathyrn Herring, et al. · Oncotarget · 24

P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC

2017 · Penella Woll, Piers Gaunt, et al. · Journal of Thoracic Oncology · 21

Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort

2018 · Mehran Afshar, Peter Fletcher, et al. · Oncotarget · 18

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer

2025 · Gary Middleton, Helen L. Robbins, et al. · npj Precision Oncology · 10

Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma

2020 · Razwan A. Razak, Peter Fletcher, et al. · Journal of Clinical Gastroenterology · 7

Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

2020 · Gary Middleton, Peter Fletcher, et al. · Nature · 4

Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)

2023 · Helen L Robbins, Peter Fletcher, et al. · Molecular Cancer Therapeutics · 2

Reply to J. Edeline et al

2022 · John Bridgewater, Peter Fletcher, et al. · Journal of Clinical Oncology · 2

PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)

2019 · G. Middleton, S. Popat, et al. · Journal of Thoracic Oncology · 2

The Impact of Lymphodepleting Chemotherapy Dose Modifications on Axicabtagene Ciloleucel Expansion and Treatment Outcome in Patients with Relapsed or Refractory CD19-Positive Diffuse Large B-Cell Lymphoma

2024 · Brijesh Gautama, Nick Duncan, et al. · Blood · 1

O-L06 The use of tumour marker Ca19.9 in the follow up of patients with resected biliary tract cancer: Results from the BILCAP randomised clinical trial

2021 · Victoria Morrison-Jones, Fangfei Gao, et al. · British journal of surgery

Has the Department of Health backed itself into a corner?: Anonymization of data may not protect against breach of confidentiality.

1999 · P Fletcher · PubMed

Works count: 13

Citation count: 242

H-index: 6

I10-index: 5